Veredus Laboratories, a supplier of molecular diagnostic tools, has launched VereMTB, a multiplexed molecular diagnostic chip capable of fast and accurate detection of mycobacterium tuberculosis complex (MTBC) and its mutations, as well as nine other clinically relevant non-tubercular mycobacterium. These mutations are responsible for resistance to multiple drugs and are reinvigorating the global spread of tuberculosis.
Conventional methods of accurately identifying TB infections can take up to 8 weeks, Veredus says. In contrast, the VereMTB test can complete the diagnosis and identify the specific mycobacterium causing the infection and drug resistance in less than three hours from sputum samples, thereby avoiding the need for culturing, the most time-consuming part of the traditional method.
Additionally, because of its compact size, the system can be deployed in a wide range of settings at the point of need.
The VereMTB multiplexed molecular diagnostic lab-on-a-chip was designed and tested
through the TM-REST program, as part of the European 7th Framework to develop new
diagnostics to fight TB and malaria.